Risk stratification in early immature and cortical/mature adult T-ALL. (A) Kaplan-Meier survival curve of early immature adult T-ALLs treated in the ECOG2993 clinical trial according to CD13 expression. (B) Kaplan-Meier survival curve of cortical/mature adult T-ALLs treated in the ECOG2993 clinical trial according to CD13 expression. (C) Kaplan-Meier survival curve of cortical/mature adult T-ALLs treated in the ECOG2993 clinical trial according to the presence or absence of homozygous CDKN2A/CDKN2B deletion. (D) Kaplan-Meier survival curve of early immature adult T-ALLs treated in the ECOG2993 clinical trial according to the presence or absence of DNMT3A mutations. (E) Kaplan-Meier survival curve of early immature adult T-ALLs treated in the ECOG2993 clinical trial according to the presence or absence of IDH1/IDH2 mutations.